

PCPT Publications – Selected manuscripts

A list of all SELECT publications can be found on this website (swog.org).

In the search bar, type in the PCPT SWOG Study # - **S9217**. Click on

Search

SWOG-9217



Chemoprevention of Prostate Cancer with Finasteride (Proscar®), Phase III, Intergroup Finasteride vs Placebo
 Eligibility for enrollment: male, >= 55 years, PS=0, DRE within normal limits, no prior prostate ca, no prior finasteride or anabolic steroids, no prior systemic therapy for cancer, must not be in urinary retention or have urinary obstructive symptoms or severe prostatism. CANCER CONTROL CREDIT: 1.0 SWOG-9217...

SWOG-9217 SWOG clinical trial number Create a Saved List Email Print

Chemoprevention of Prostate Cancer with Finasteride (Proscar®), Phase III, Intergroup

Closed Phase —

100% Accrual

Published

Abbreviated Title	PROSTATE CANCER PREVENTION TRIAL
Activated	10/13/1993
Closed	12/06/1996
Study chair(s)	Ian M. Thompson Jr., MD

Research committees Genitourinary Cancer Prevention **Treatment** Finasteride

Eligibility Criteria +

Publication Information +

Below is a listing of some of the key publications on the trial, its design and outcomes.

Year	Reference
1995	Design of the prostate cancer prevention trial (PCPT). P Feigl, B Blumenstein I Thompson, et al. Controlled Clinical Trials 16: 150 – 163, 1995.
2003	The influence of finasteride on the development of prostate cancer. IM Thompson PJ Goodman, CM Tangen, et al. New England Journal of Medicine 349: 215-224, 2003.
2004	Implementation of the prostate cancer prevention trial (PCPT). PJ Goodman CM Tangen JJ Crowley, et al. Controlled Clinical Trials 25: 203-222, 2004. PubMed PMID: 16697846.

2006	The prostate cancer prevention trial: design, biases and interpretation of study results. PJ Goodman, IM Thompson Jr, CM Tangen, et al. Journal of Urology 175:2234-2242, 2006. PubMed PMID: 16697846.
2007	Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. MS Lucia, JI Epstein, PJ Goodman, et al. Journal of the National Cancer Institute 99(18):1375-1383, 2007. PubMed PMID: 17848673.
2008	Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. MW Redman, CM Tangen, PJ Goodman et al. Cancer Prevention Research 1(3):174-81, 2008. PubMed PMID: 19138953; PubMed Central PMCID: PMC2844801.
2008	Pathologic characteristics of cancer detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. MS Lucia, A Darke, PJ Goodman, et al. Cancer Prevention Research 1(3): 167-173, 2008. PubMed PMID: 19138952; PubMed Central PMCID: PMC3985428.
2010	Transition of a clinical trial into translation research: the Prostate Cancer Prevention Trial experience. PJ Goodman, CM Tangen, A Kristal, et al. Cancer Prevention Research, 3 (12): 1523-1533, 2010. PubMed PMID: 21149329; PubMed Central PMCID: PMC3058741.
2013	Long-term survival of participants in the Prostate Cancer Prevention Trial. IM Thompson, PJ Goodman, CM Tangen, et al. New England Journal of Medicine 369 (7): 603-610, 2013. PubMed PMID: 23944298; PubMed Central PMCID: PMC4141537.
2014	Factors associated with adherence to an end-of-study biopsy: lessons from the Prostate Cancer Prevention Trial (SWOG-Coordinated Intergroup study S9217). ER Gritz, KB Arnold, CM Moinpour, et al. CEBP, 2014. PubMed PMID: 25028457; PubMed Central PMCID: PMC4119542.
2014	Statin drug use is not associated with prostate cancer risk in men who are regularly screened. Platz EA, Tangen CM, Goodman PJ, Till C, Parnes HL, Figg WD, Albanes D, Neuhaus ML, Klein EA, Lucia MS, Thompson IM Jr, Kristal AR. J Urol. 2014 Aug;192(2):379-84. doi: 10.1016/j.juro.2014.01.095. Epub 2014 Feb 8. PubMed PMID: 24518774; PubMed Central PMCID: PMC4104140.
2015	Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Chau CH, Price DK, Till C, Goodman PJ, Chen X, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Tangen CM, Chu L, Parnes HL, Schenk JM, Reichardt JK, Thompson IM, Figg WD. PLoS One. 2015 May 8;10(5):e0126672. doi: 10.1371/journal.pone.0126672. eCollection 2015. PubMed PMID: 25955319; PubMed Central PMCID: PMC4425512.
2015	Prospective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. Sutcliffe S, Till C, Jenkins FJ, Gaydos CA, Goodman PJ, Hoque AM, Hsing AW, Thompson IM, Nelson WG, De Marzo

	AM, Platz EA. Cancer Causes Control. 2015 Jan;26(1):35-44. doi: 10.1007/s10552-014-0480-5. Epub 2014 Oct 31. PubMed PMID: 25359302; PubMed Central PMCID: PMC4282945.
2015	Association between serum phospholipid fatty acids and intraprostatic inflammation in the placebo arm of the Prostate Cancer Prevention Trial. Nash SH, Schenk JM, Kristal AR, Goodman PJ, Lucia MS, Parnes HL, Thompson IM, Lippman SM, Song X, Gurel B, De Marzo A, Platz EA. Cancer Prev Res (Phila). 2015 Jul;8(7):590-6. doi: 10.1158/1940-6207.CAPR-14-0398. Epub 2015 Apr 29. PubMed PMID: 25926387; PubMed Central PMCID: PMC4491033.
2015	Serum retinol and carotenoid concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Nash SH, Till C, Song X, Lucia MS, Parnes HL, Thompson IM Jr, Lippman SM, Platz EA, Schenk J. Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1507-15. doi: 10.1158/1055-9965.EPI-15-0394. Epub 2015 Aug 12. PubMed PMID: 26269564; PubMed Central PMCID: PMC4592455.
2015	Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. Schenk JM, Till C, Hsing AW, Stanczyk FZ, Gong Z, Neuhaus ML, Reichardt JK, Hoque AM, Figg WD, Goodman PJ, Tangen CM, Thompson IM. Cancer Causes Control. 2016 Feb;27(2):175-82. doi: 10.1007/s10552-015-0695-0. Epub 2015 Nov 20. PubMed PMID: 26589415; PubMed Central PMCID: PMC4724283.
2015	Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippman SM, Parnes HL, Dlugniewski PJ, Isaacs WB, De Marzo AM, Drake CG, Platz EA. Prostate. 2015 Sep;75(13):1403-18. doi: 10.1002/pros.23021. Epub 2015 Jun 5. PubMed PMID: 26047319; PubMed Central PMCID: PMC4536102.
2015	Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial. Winchester DA, Gurel B, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Thompson IM, Xu J, Zheng SL, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, Drake CG, De Marzo AM, Platz EA. Prostate. 2016 May;76(6):565-74. doi: 10.1002/pros.23147. Epub 2016 Jan 15. PubMed PMID: 26771888; PubMed Central PMCID: PMC4841624.
2016	Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Parnes HL, Schenk JM, Tangen CM, Thompson IM, Reichardt JK, Figg WD. Cancer. 2016 Aug 1;122(15):2332-40. doi: 10.1002/cncr.30071. Epub 2016 May 10. PubMed

	PMID:27164191; PubMed Central PMCID: PMC4956504.
2016	Long-term consequences of finasteride vs placebo in the Prostate Cancer Prevention Trial. Unger JM, Till C, Thompson IM Jr, Tangen CM, Goodman PJ, Wright JD, Barlow WE, Ramsey SD, Minasian LM, Hershman DL. J Natl Cancer Inst. 2016 Aug 26;108(12). pii: djw168. doi: 10.1093/jnci/djw168. Print 2016 Dec. PubMed PMID: 27565902; PubMed Central PMCID: PMC5241895.
2016	Biases in recommendations for and acceptance of prostate biopsy significantly affect assessment of prostate cancer risk factors: results from two large randomized clinical trials. Tangen CM, Goodman PJ, Till C, Schenk JM, Lucia MS, Thompson IM Jr. J Clin Oncol. 2016 Dec 20;34(36):4338-4344. Epub 2016 Oct 28. PubMed PMID: 27998216; PubMed Central PMCID: PMC5455311.